Molecular Data Stock Performance

MKDTY Stock  USD 0.0001  0.00  0.00%   
Molecular Data holds a performance score of 7 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 3.55, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Molecular Data will likely underperform. Use Molecular Data variance and rate of daily change , to analyze future returns on Molecular Data.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Data are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, Molecular Data showed solid returns over the last few months and may actually be approaching a breakup point. ...more
  

Molecular Data Relative Risk vs. Return Landscape

If you would invest  0.01  in Molecular Data on October 29, 2025 and sell it today you would earn a total of  0.00  from holding Molecular Data or generate 0.0% return on investment over 90 days. Molecular Data is currently producing 2.4731% returns and takes up 25.4356% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Molecular, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Molecular Data is expected to generate 33.94 times more return on investment than the market. However, the company is 33.94 times more volatile than its market benchmark. It trades about 0.1 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

Molecular Data Target Price Odds to finish over Current Price

The tendency of Molecular Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.0001 90 days 0.0001 
about 71.19
Based on a normal probability distribution, the odds of Molecular Data to move above the current price in 90 days from now is about 71.19 (This Molecular Data probability density function shows the probability of Molecular Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the pink sheet has the beta coefficient of 3.55 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Molecular Data will likely underperform. In addition to that Molecular Data has an alpha of 2.0615, implying that it can generate a 2.06 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Molecular Data Price Density   
       Price  

Predictive Modules for Molecular Data

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Molecular Data. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Molecular Data's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.00007125.44
Details
Intrinsic
Valuation
LowRealHigh
0.000.000225.44
Details
Naive
Forecast
LowNextHigh
0.0000030.000125.44
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.00020.00020.0002
Details

Molecular Data Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Molecular Data is not an exception. The market had few large corrections towards the Molecular Data's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Molecular Data, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Molecular Data within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
2.06
β
Beta against Dow Jones3.55
σ
Overall volatility
0.0001
Ir
Information ratio 0.09

Molecular Data Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Molecular Data for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Molecular Data can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Molecular Data is way too risky over 90 days horizon
Molecular Data has some characteristics of a very speculative penny stock
Molecular Data appears to be risky and price may revert if volatility continues

About Molecular Data Performance

Evaluating Molecular Data's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Molecular Data has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Molecular Data has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.

Things to note about Molecular Data performance evaluation

Checking the ongoing alerts about Molecular Data for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Molecular Data help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Molecular Data is way too risky over 90 days horizon
Molecular Data has some characteristics of a very speculative penny stock
Molecular Data appears to be risky and price may revert if volatility continues
Evaluating Molecular Data's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Molecular Data's pink sheet performance include:
  • Analyzing Molecular Data's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Molecular Data's stock is overvalued or undervalued compared to its peers.
  • Examining Molecular Data's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Molecular Data's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Molecular Data's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Molecular Data's pink sheet. These opinions can provide insight into Molecular Data's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Molecular Data's pink sheet performance is not an exact science, and many factors can impact Molecular Data's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Molecular Pink Sheet Analysis

When running Molecular Data's price analysis, check to measure Molecular Data's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Data is operating at the current time. Most of Molecular Data's value examination focuses on studying past and present price action to predict the probability of Molecular Data's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Data's price. Additionally, you may evaluate how the addition of Molecular Data to your portfolios can decrease your overall portfolio volatility.